Pre‐clinically, treatment with inhibitory peptide blocking RBM10‐RORB interaction suppresses lysosomal biogenesis and aggressive features of tumor cells, highlighting the biological significance of RBM10/RORB/NF‐κB axis in NB progression. The gene discussed is RBM10; the disease is neoplasm.